Periodic Reporting for period 1 - CUSTOMI Arch (New materials for revolutionary, branched, non-supported stents (CUSTOMI™) for aortic-arch endovascular repair)
Periodo di rendicontazione: 2016-08-01 al 2017-01-31
ENDONOV
SME Instrument Phase 1 FINAL REPORT Summary
Aortic dissection and aneurysms are the two most common life-threatening disorders affecting the aorta. Unless they are treated immediately, they result in shock and death in 80% of cases. However, according to Prof. Koskas, today up to 50% of patients with a high surgical risk cannot be treated with traditional open surgery. This implies that new and less invasive interventions are urgently needed. This is not only a European challenge, but a global one that impacts patients worldwide.
Endonov is developing a disruptive solution called the CUSTOMI® Arch Branched stent system to overcome these existing problems.
New woven fabric materials and advanced manufacturing procedures are playing a crucial role in CUSTOMI®’s unique design and fabrication. For the first time, smaller, tailor-made and multi-branched stent-grafts will be able to take the shape of the complex aortic arch anatomy of each patient. This medical device will be implanted and positioned with greater precision using an advanced sensor guided delivery system. This will allow to treat much more patients with different arch anatomies and ensure a longer term durability of the device.
The specific objectives of the feasibility study were to cover technological, IP and economic feasibility for the Customi ® Arch Branched System. In particular, to validate both the new fabric and delivery system. This feasibility study was essential, and a first step before moving forward to preclinical and clinical trials during the SME Instrument Phase 2.
SME Instrument Phase 1 FINAL REPORT Summary
Aortic dissection and aneurysms are the two most common life-threatening disorders affecting the aorta. Unless they are treated immediately, they result in shock and death in 80% of cases. However, according to Prof. Koskas, today up to 50% of patients with a high surgical risk cannot be treated with traditional open surgery. This implies that new and less invasive interventions are urgently needed. This is not only a European challenge, but a global one that impacts patients worldwide.
Endonov is developing a disruptive solution called the CUSTOMI® Arch Branched stent system to overcome these existing problems.
New woven fabric materials and advanced manufacturing procedures are playing a crucial role in CUSTOMI®’s unique design and fabrication. For the first time, smaller, tailor-made and multi-branched stent-grafts will be able to take the shape of the complex aortic arch anatomy of each patient. This medical device will be implanted and positioned with greater precision using an advanced sensor guided delivery system. This will allow to treat much more patients with different arch anatomies and ensure a longer term durability of the device.
The specific objectives of the feasibility study were to cover technological, IP and economic feasibility for the Customi ® Arch Branched System. In particular, to validate both the new fabric and delivery system. This feasibility study was essential, and a first step before moving forward to preclinical and clinical trials during the SME Instrument Phase 2.
During this first phase, we have been able to validate the capability of our main partner SATAB to develop and manufacture a new generation of textile. It was very important to first ensure it before engaging further in new development. The comparable material that we have produced and tested outperforms in many ways our current supplier’s. The development of a new polyethylene based material and weaving technique will be part of our next phase of development.
In order to position the device in a complex 3D environment, a new advanced delivery system must be developed. Thanks to the work done in the present phase, we now have a full specification as well as preliminary drawings. Our partner Transluminal is now ready to supply the first prototypes.
Thanks to SME instrument phase 1, we have confirmed the interest of our research all well as validated some major hypothesis. In particular regarding marketing, we were able to confirm and validate the existence of the unmet medical need we are addressing, analyzing key stakeholders, refining our market access strategy and compute future revenue. We are now ready to engage in the full development of a device that will enable health professionals to treat much more patients.
A complete status of the company strong IP position is given in this report, however a full analysis of our freedom to operate will be performed at a later stage of the project.
In order to position the device in a complex 3D environment, a new advanced delivery system must be developed. Thanks to the work done in the present phase, we now have a full specification as well as preliminary drawings. Our partner Transluminal is now ready to supply the first prototypes.
Thanks to SME instrument phase 1, we have confirmed the interest of our research all well as validated some major hypothesis. In particular regarding marketing, we were able to confirm and validate the existence of the unmet medical need we are addressing, analyzing key stakeholders, refining our market access strategy and compute future revenue. We are now ready to engage in the full development of a device that will enable health professionals to treat much more patients.
A complete status of the company strong IP position is given in this report, however a full analysis of our freedom to operate will be performed at a later stage of the project.
We are on our way to produce a thinner and stronger sheath material that will surpasse any of existing textile available on the market. Without such advanced research and its consequences on the reduction of the overall size of the device, the develpment of a specific endo prothesis to treat the aortic arch aneuvrism will be much more difficult.
In fact, as demonstrated in our report, none of the current players (and we are talking of very large US corporations) have shown any convincing progres over the last years.
The market available to the company that will be able to finalise the development of such a device represents more that €120 M for that one device only.
Moreover, the availability of the new device will allow patients that have no or unsatisfactory solutions to be much better treated.
In fact, as demonstrated in our report, none of the current players (and we are talking of very large US corporations) have shown any convincing progres over the last years.
The market available to the company that will be able to finalise the development of such a device represents more that €120 M for that one device only.
Moreover, the availability of the new device will allow patients that have no or unsatisfactory solutions to be much better treated.